METHODS: A retrospective review of patients with metastatic NENs receiving PRRT was undertaken. Pre-treatment FDG-PET images were analyzed and variables collected included MTV and TLG (dichotomized by median into high vs low). Main Outcomes were overall survival (OS) and progression-free survival (PFS) by MTV and TLG (high vs low).
RESULTS: One hundred five patients were included. Median age was 64 years (50% male). Main primary NEN sites were small bowel (43.8%) and pancreas (40.0%). Median MTV was 3.8 mL and median TLG was 19.9. Dichotomization formed identical cohorts regardless of whether MTV or TLG were used. Median OS was 72 months; OS did not differ based on MTV/TLG high versus low (47.4 months vs not reached; hazard ratio, 0.43; 95% confidence interval [CI], 0.18-1.04; P = 0.0594). Median PFS was 30.4 months; PFS differed based on MTV/TLG high versus low (21.6 months vs 45.7 months; hazard ratio, 0.35; 95% CI, 0.19-0.64; P = 0.007).
CONCLUSIONS: Low MTV/TLG on pre-treatment FDG-PET was associated with longer PFS in metastatic NEN patients receiving PRRT.
方法:对接受PRRT的转移性NENs患者进行回顾性分析。分析治疗前的FDG-PET图像,收集的变量包括MTV和TLG(由中位数分为高和低)。主要结果是MTV和TLG的总生存期(OS)和无进展生存期(PFS)(高与低)。
结果:纳入了105名患者。中位年龄为64岁(50%为男性)。主要NEN部位为小肠(43.8%)和胰腺(40.0%)。MTV中位数为3.8mL,TLG中位数为19.9。无论是否使用MTV或TLG,二分法都形成相同的队列。中位OS为72个月;OS根据MTV/TLG高与低(47.4个月与未达到;风险比,0.43;95%置信区间[CI],0.18-1.04;P=0.0594)。PFS中位数为30.4个月;PFS基于MTV/TLG高与低(21.6个月与45.7个月;风险比,0.35;95%CI,0.19-0.64;P=0.007)。
结论:在接受PRRT的转移性NEN患者中,治疗前FDG-PET的MTV/TLG低与PFS延长相关。